Abstract 643P
Background
Chimeric antigen receptor (CAR) T-cell treatment demonstrates remarkable clinical success in B-cell malignancies. According to the data from clinicaltrials.gov, China currently outstands as the country with the most registered CAR-T trials worldwide. However, no data is available on the overall efficacy of multiple CAR-T products in the treatment of Chinese patients with RRMM. To this end, we conducted this scoping review to summarize the clinical outcome of CAR-T therapy in the Chinese RRMM.
Methods
We systematically searched literatures in the Chinese RRMM patients from the databases and international conferences website. The publication time was restricted to be between 2005 January 1 and 2021 September 6. 40 interventional studies were ultimately screened out and 21 CAR-T pivotal clinical research were selected for analysis. Meta-analysis method was used to estimate the efficacy results.
Results
A total of 552 RRMM patients were incorporated as an analytical entity. The pooled median lines of prior therapy were 4. Patients who experienced prior CAR-modified cellular therapy and who were heavily pretreated with more than 4 lines could still benefit from next line CAR-T treatment. The pooled median PFS was 14.42 months (4 studies were collectively assessed). The overall response rate was impressive, ranging from 80% to 100%. The rate of complete response (CR) ranged broadly, from 29% to 82% in total 21 studies. The analysis found that the CR of dual-target CAR-T and single-target CAR-T was 57% and 59% respectively. The CR in the studies with humanized/human CAR-T was 57% and 59% in total 21 studies. The CR of scFV CAR-T and VHH CAR-T was 58% and 68% respectively. The MRD negativity rate of all the recipients was approximately 68.4%-100% (Flow cytometry with sensitivity of 10-5).
Conclusions
CAR-T investigational trials were widely carried out in China. As a promising therapeutic modality with new mechanism of action, it provides an efficacious option for Chinese patients with RRMM. Patients at advanced stage can gain deep response from CAR-T therapy, regardless of the prior treatment regimens.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Janssen Pharmaceutical Co., Ltd.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.